Facebook Falters Amid Political Pressure on Libra Digital Currency

Surprise, surprise: Regulatory opposition toward digital currencies at home and abroad is rising against Facebook.

Deutsche Bank Stock Declines as Transformation Plan Sinks In

Deutsche is looking to drop the "bad bank" moniker with big moves on Monday.

2 Attractive Biotechs With Key Study Outcomes on the Horizon

Intra-Cellular Therapies and Acadia Pharmaceuticals are worth investors' attention.

Boeing Loses Altitude as FAA Finds More Risks Related to 737 MAX

The Federal Aviation Administration has declined to set a timeline on when it will lift its order prohibiting the troubled aircraft from flying.

Trump-Xi Face Off, Potential EU Land Mines and a Caterpillar Play: Market Recon

The G-20 Summit in Japan could hold more intrigue than just the planned meeting between President Trump and Xi.

Micron's Surge Causes Skeptics to Step Back

A number of vocal analysts and investors are calling for caution on those eager to buy the semiconductor stock amidst its Wednesday morning leap.

Micron's Unexpected Move Higher Boosts Semiconductor Sentiment

Micron is motivating more positive outlook on the semiconductor sector's road ahead.

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Despite the financial positivity, many analysts warn the deal could have hiccups ahead.

Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015

PFE was ready to pay $160 billion until U.S. regulators blocked the deal.

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.